This is a repository copy of A place for precision medicine in bladder cancer: targeting the FGFRs.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/102184/

Version: Accepted Version

Article:
Di Martino, E, Tomlinson, DC orcid.org/0000-0003-4134-7484, Williams, SV et al. (1 more author) (2016) A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncology, 12 (19). pp. 2243-2263. ISSN 1479-6694

https://doi.org/10.2217/fon-2016-0042

© 2016 Future Medicine Ltd. This is an author produced version of a paper published in Future Oncology. Uploaded in accordance with the publisher's self-archiving policy.

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Figure 2. A. Distribution of FGFR3 point mutations according to bladder tumour stage. B. FGFR3 protein expression in relation to mutation according to bladder tumour stage. Expression above that in normal urothelium is defined as “high” and the same or lower levels than normal urothelium as “low”. Data is from a one-year cohort of patients from a single institution. Adapted from reference 51.